Protein defects in neuromuscular diseases

Brazilian Journal of Medical and Biological Research

Volumn 36, Issue 5, 2003, Pages 543-555

  Vainzof, M ^a   Zatz, M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dystrophin; Muscle proteins; Muscular dystrophies; Sarcoglycans

Indexed keywords

CALPAIN 3; CAVEOLIN 3; CELL PROTEIN; COLLAGEN TYPE 6; CONNECTIN; DYSFERLIN; DYSTROPHIN; EMERIN; LAMIN A; LAMIN C; LAMININ; MUSCLE PROTEIN; NEBULIN; NUCLEAR PROTEIN; SARCOGLYCAN; SCLEROPROTEIN;

ANTIBODY SPECIFICITY; CELL NUCLEUS; CYTOSOL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL RESEARCH; MOTONEURON; MUSCLE DEVELOPMENT; MUSCLE FIBER MEMBRANE; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; PELVIS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; SARCOLEMMA; SARCOMERE; SHOULDER GIRDLE; WESTERN BLOTTING;

EID: 0037942565     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2003000500001     Document Type: Review

References (62)

1. Koenig M, Monaco AP & Kunkel LM (1988). The complete sequence of dystrophin predicts rod-shaped cytoskeletal protein. Cell, 53: 219-228.
2. Hoffman EP, Brown RH & Kunkel LM (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 51: 919-928.
3. Bushby KMD (1999). The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms. Human Molecular Genetics, 8: 1875-1882.
4. Zatz M, Vainzof M & Passos-Bueno MR (2000). Limb-girdle muscular dystrophy: one gene with different phenotypes, one phenotype with different genes. Current Opinion in Neurology, 13: 511-517.
5. Hauser MA, Horrigan SK, Salmikangas P, Viles KD, Tim RW, Torian UM & Anu T (2000). A mutation in the Myotilin gene causes limb-girdle muscular dystrophy 1A. Human Molecular Genetics, 9: 2141-2147.
6. Van der Kooi A, Van Meegen M, Ledderhof TM, McNally EM, de Visser M & Bolhuis PA (1997). Genetic localization of a newly recognized autosomal dominant limb-girdle muscular dystrophy with cardiac involvement (LGMD1B) to chromosome 1q11-21. American Journal of Human Genetics, 60: 891-895.
7. Minetti C, Sotgia F, Bruno C et al. (1998). Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nature Genetics, 18: 365-368.
8. McNally EM, de Sa Moreira E, Duggan DJ et al. (1998). Caveolin-3 in muscular dystrophy. Human Molecular Genetics, 7: 871-878.
9. Messina DI, Speer MC, Pericak-Vance MA & McNally EM (1997). Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. American Journal of Human Genetics, 61: 909-917.
10. Speer MC, Vance JM, Grubber JM et al. (1999). Identification of a new autosomal dominant limb-girdle muscular dystrophy locus on chromosome 7. American Journal of Human Genetics, 64: 556-562.
11. Feit H, Silbergleit A, Schneider LB et al. (1998). Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31. American Journal of Human Genetics, 63: 1732-1742.
12. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG & Campbell KP (1990). Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature, 345: 315-319.
13. Yoshida M & Ozawa E (1990). Glycoprotein complex anchoring dystrophin to sarcolemma. Journal of Biochemistry, 108: 748-752.
14. Richard I, Broux O, Allamand V et al. (1995). Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell, 81: 27-40.
15. Bashir R, Britton S, Strachan T et al. (1998). A gene related to the C. elegans spermatogenesis factor fer-1 is mutated in patients with limb-girdle muscular dystrophy type 2B (LGMD2B). Nature Genetics, 20: 37-42.
16. Liu J, Aoki M, Illa I et al. (1998). Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nature Genetics, 20: 31-36.
17. Valle G, Faulkner G, De Antoni A, Pacchioni B, Pallavicini A, Pandolfo D, Tiso N, Toppo S, Trevisan S & Lanfranchi G (1997). Telethonin, a novel sarcomeric protein of heart and skeletal muscle. FEBS Letters, 415: 163-168.
18. Moreira ES, Wiltshire TJ, Faulkner G et al. (2000). Limb-girdle muscular dystrophy type 2G (LGMD2G) is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nature Genetics, 24: 163-166.
19. Brockington M, Blake DJ, Prandini P et al. (2001). Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. American Journal of Human Genetics, 69: 1198-1209.
20. Brockington M, Yuva Y, Prandini P et al. (2001). Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 21 as a milder allelic variant of congenital muscular dystrophy MDC1C. Human Molecular Genetics, 10: 2851-2859.
21. Frosk P, Weiler T, Nylen E, Sudha T, Greenberg CR, Morgan K, Fujiwara TM & Wrogemann K (2002). Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. American Journal of Human Genetics, 70: 663-672.
22. Weiler T, Greenberg CR, Zelinski T, Nylen E, Coghlan G, Crumley MJ, Fujiwara TM, Morgan K & Wrogemann K (1998). A gene for autosomal recessive limb-girdle muscular dystrophy in Manitoba Hutterites maps to chromosome region 9q31-q33: evidence for another LGMD locus. American Journal of Human Genetics, 63: 140-147.
23. Haravuori H, Vihola A, Straub V et al. (2001). Secondary calpain3 deficiency in 2q-linked muscular dystrophy: titin is the candidate gene. Neurology, 56: 869-877.
24. Anderson LVB (2001). Multiplex Western blot analysis of the muscular dystrophy proteins. In: Bushby KMD & Anderson LVB (Editors), Muscular Dystrophy: Methods and Protocols. Chapter 22 (number 43 in the Methods in Molecular Medicine series). Humana Press, Totowa, NJ, 369-386.
25. Campbell KP & Kahl SD (1989). Association of dystrophin and an integral membrane glycoprotein. Nature, 338: 259-262.
26. Hack AA, Groh ME & McNally EM (2000). Sarcoglycans in muscular dystrophy. Microscopy Research and Technique, 48: 167-180.
27. Cohn RD & Campbell KP (2000). Molecular basis of muscular dystrophies. Muscle and Nerve, 23: 1456-1471.
28. Bakker E & Van Ommen GB (1998). Duchenne and Becker muscular dystrophy DMD and BMD). In: Emery AEH (Editor), Neuromuscular Disorders. Clinical and Molecular Genetics. John Wiley & Sons, New York, 59-85.
29. Nicholson LV, Johnson MA, Gardner-Medwin G, Bhattacharya S & Harris JB (1990). Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy. Acta Neuropathologica, 80: 239-250.
30. Vainzof M, Pavanello RCM, Pavanello I, Passos-Bueno MR, Rapaport D & Zatz M (1990). Dystrophin immunostaining in muscles from patients with different types of muscular dystrophy: A Brazilian study. Journal of Neurological Sciences, 98: 221-233.
31. Vainzof M, Zubrzycka-Gaarn EE, Rapaport D, Passos-Bueno MR, Pavanello I & Zatz MZ (1991). Immunofluorescence dystrophin study in Duchenne dystrophy through the concomitant use of two antibodies directed against the carboxy-terminal and the amino-terminal region of the protein. Journal of Neurological Sciences, 101: 141-147.
32. Vainzof M, Passos-Bueno MR, Pavanello RCM & Zatz M (1995). Is dystrophin always altered in Becker muscular dystrophy patients? Journal of Neurological Sciences, 131: 99-104.
33. Vainzof M, Passos-Bueno MR, Rapaport D, Pavanello RCM, Bulman DE & Zatz M (1992). Additional dystrophin fragment in Becker muscular dystrophy patients: Correlation with the pattern of DNA deletions. American Journal of Human Genetics, 44: 382-384.
34. Vainzof M, Passos-Bueno MR, Pavanello RCM, Marie SK & Zatz M (1999). Sarcoglycanopathy is responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy. Journal of Neurological Sciences, 164: 44-49.
35. Moreira ES, Vainzof M, Suzuki OT, Pavanello RCM, Zatz M & Passos-Bueno MR (2003). Genotype-phenotype correlations in 35 Brazilian families with sarcoglycaropathies including the description of three novel mutations. Journal of Medical Genetics, 40: E12.
36. Bönnemann CG (1999). Limb-girdle muscular dystrophies: an overview. Journal of Child Neurology, 14: 31-33.
37. Vainzof M, Passos-Bueno MR, Moreira ES et al. (1996). The sarcoglycan complex in the six autosomal recessive limb-girdle (AR-LGMD) muscular dystrophies. Human Molecular Genetics, 5: 1963-1969.
38. Vainzof M, Moreira ES, Canovas M, Suzuki OT, Pavanello RCM, Costa CS, Passos-Bueno MR & Zatz M (2000). Partial α-sarcoglycan deficiency associated with the retention of the SG complex in a LGMD2D family. Muscle and Nerve, 23: 984-988.
39. Paula F, Vainzof M, Passos-Bueno MR, Pavanello RCM, Matioli SR, Anderson LVB, Nigro V & Zatz M (2002). Clinical variability in calpainopathy: What makes the difference? European Journal of Human Genetics, 10: 825-832.
40. Anderson LV, Davison K, Moss JA, Richard I, Fardeau M, Tome FM, Hubner C, Lasa A, Colomer J & Beckmann JS (1998). Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A. American Journal of Pathology, 153: 1169-1179.
41. Vainzof M, Anderson LVB, Moreira ES, Paula F, Pavanello RCM, Passos-Bueno MR & Zatz M (2000). Calpain 3: Characterization of the primary defect in LGMD2A and analysis of its secondary effect in other LGMDs. Neurology, 54: A436 (Abstract).
42. Vainzof M, Moreira ES, Passos-Bueno MR et al. (2002). The effect of telethonin deficiency in LGMD-2G and its expression in other forms of muscular dystrophies and congenital myopathies. Biochimica et Biophysica Acta - Genetic Basis of Diseases, 1588: 33-40.
43. Anderson LV, Harrison RM, Pogue R et al. (2000). Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscular Disorders, 10: 553-559.
44. Vainzof M, Pavanello RCM, Anderson LVB, Moreira ES, Passos-Bueno MR & Zatz M (2001). Dysferlin analysis in autosomal recessive limb-girdle muscular dystrophies (AR-LGMD). Journal of Molecular Neuroscience, 17: 71-80.
45. Bushby K & Beckmann J (2003). The 105th ENMC workshop-pathogenesis in the non-sarcoglycan limb-girdle muscular dystrophies. Neuromuscular Disorders, 13: 80-90.
46. Anderson LV, Davison K, Moss JA et al. (1999). Dysferlin is a plasma membrane protein and is expressed early in human development. Human Molecular Genetics, 8: 855-861.
47. Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Illa I & Brown Jr RH (2002). A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Annals of Neurology, 51: 129-133.
48. Matsuda C, Hayashi YK, Ogawa M, Aoki M, Murayama K, Nishino I, Nonaka I, Arahata K & Brown Jr RH (2001). The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Human Molecular Genetics, 10: 1761-1766.
49. Gregorio CC, Granzier H, Sorimachi H & Labeit S (1999). Muscle assembly: a titanic achievement? Current Opinion in Cell Biology, 11: 18-25.
50. Wallgren-Pettersson C & Laing NG (2001). Report of the 83rd ENMC International Workshop: 4th Workshop on Nemaline Myopathy. Neuromuscular Disorders, 11: 589-595.
51. Gurgel-Giannetti J, Reed UC, Bang ML et al. (2001). Nebulin expression in Nemaline myopathy. Neuromuscular Disorders, 11: 154-162.
52. Vainzof M (2001). Miopatias congênitas. In: Carakushansky G (Editor), Doenças Genéticas em Pediatria. Guanabara Koogan S/A, Rio de Janeiro, RJ, Brazil.
53. Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G & Toniolo D (1994). Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nature Genetics, 8: 323-327.
54. Bonne G, Di Barletta MR, Varnous S et al. (1999). Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nature Genetics, 21: 285-288.
55. Lefebvre S, Burglen L, Reboullet S et al. (1995). Identification and characterization of a spinal muscular atrophy-determining gene, Cell, 80: 155-165.
56. Young PJ, Le TT, Dunckley M, Nguyen TM, Burghes AH & Morris GE (2001). Nuclear gems and Cajal (coiled) bodies in fetal tissues: nucleolar distribution of the spinal muscular atrophy protein, SMN. Experimental Cell Research, 265: 252-261.
57. Hillaire D, Leclerc A, Faure S et al. (1994). Localization of merosin-negative congenital muscular dystrophy to chromosome 6q2 by homozygosity mapping. Human Molecular Genetics, 3: 1657-1661.
58. Vainzof M, Reed UC, Schwartzman JS, Pavanello RCM, Passes-Bueno MR & Zatz M (1995). Deficiency of merosin (laminin M or α2) in congenital muscular dystrophy associated with cerebral white matter alterations. Neuropediatrics, 26: 293-297.
59. Sewry CA, Naom I, D'Alessandro M, Sorokin L, Bruno S, Wilson LA, Dubowitz V & Muntoni F (1997). Variable clinical phenotype in merosin-deficient congenital muscular dystrophy associated with differential immunolabelling of two fragments of the laminin alpha 2 chain. Neuromuscular Disorders, 7: 169-175.
60. Naom I, D'Alessandro M, Sewry CA, Jardine P, Ferlini A, Moss T, Dubowitz V & Muntoni F (2000). Mutations in the laminin alpha2-chain gene in two children with early-onset muscular dystrophy. Brain, 123: 31-41.
61. Muntoni F, Brockington M, Blake DJ, Torelli S, Cegrí CA & Brown SC (2002). Disorders of glycosylation: an emerging group of muscular dystrophies. Neuromuscular Disorders, 12: 718.
62. Pepe G, Bertini E, Ronaldo P et al, (2002). Bethlem myopathy (BETHLEM) and Ullrich scleroatonic muscular dystrophy: 100th ENMC International Workshop, November 23-24, 2001, Naarden, The Netherlands. Neuromuscular Disorders, 12: 984-993.